Zenere Therapeutics

Zenere Therapeutics is a preclinical-stage biotechnology company dedicated to developing transformative small molecule therapies for neurodegenerative disorders, with a primary focus on Parkinson's disease. The company's core research centers on the development of potent and selective inhibitors of Leucine-rich repeat kinase 2 (LRRK2), a key genetic driver of Parkinson's pathology. Founded by industry veterans and leading academic researchers from the National Institutes of Health (NIH), Zenere leverages deep biological insights to address the underlying causes of neuronal degradation. Their lead program aims to provide disease-modifying treatments that can slow or halt the progression of neurodegenerative conditions. The company is currently optimizing its lead candidates for future clinical evaluation.